Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30004437 | 0.93 | KMT2A (0.48) | KMT2AMDM4TP53CASP3FDFT1 | |
| SCHEMBL5963320 | 0.93 | KMT2A (0.48) | KMT2AMDM4TP53CASP3FDFT1 | |
| SCHEMBL18740102 | 0.84 | KMT2A (0.63) | KMT2ACASP3 | |
| SCHEMBL30570803 | 0.84 | KMT2A (0.63) | KMT2ACASP3 | |
| SCHEMBL30554761 | 0.84 | KMT2A (0.51) | KMT2AMDM4TP53CASP3FDFT1 | |
| SCHEMBL14787476 | 0.84 | KMT2A (0.51) | KMT2AMDM4TP53CASP3FDFT1 | |
| SCHEMBL2245010 | 0.83 | KMT2A (0.54) | KMT2APTPN1MDM4TP53CASP3 | |
| SCHEMBL2245718 | 0.81 | PTPN1 (0.53) | KMT2APTPN1MDM4TP53 | |
| SCHEMBL14787175 | 0.80 | MDM4 (0.48) | KMT2AMDM4TP53CASP3FDFT1 | |
| SCHEMBL26980963 | 0.80 | TLR2 (0.54) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119073-B2 | Peptides and their use as inhibitors of hepatitis C virus ns3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2006-10-10 | — | — | US | disclosed |
| US-20040142876-A1 | Peptides and their use as inhibitors of hepatitis c virus ns3 protease | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142876-A1 | Peptides and their use as inhibitors of hepatitis c virus ns3 protease | CTRL, VIP, CTSC | KMT2A 4234/4885PTPN1 756/4885MDM4 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.